Khaled W.D. Alsenawi, Massa Salahi Alasbahi, Berrin Erdağ. Dual-target CD19/BCMA CAR-T cell therapy in systemic lupus erythematosus and myasthenia gravis: current evidence and future directions. // Clinical Immunology Communications. – DOI: 10.1016/j.clicom.2026.100145. – URL: https://www.sciencedirect.com/science/article/pii/S2772613426000326?dgcid=rss_sd_all
Khaled W.D. Alsenawi, Massa Salahi Alasbahi, & Berrin Erdağ Dual-target CD19/BCMA CAR-T cell therapy in systemic lupus erythematosus and myasthenia gravis: current evidence and future directions. Clinical Immunology Communications. https://doi.org/10.1016/j.clicom.2026.100145
Khaled W.D. Alsenawi, et al. “Dual-target CD19/BCMA CAR-T cell therapy in systemic lupus erythematosus and myasthenia gravis: current evidence and future directions.” Clinical Immunology Communications. doi:10.1016/j.clicom.2026.100145.
@article{Alsenawi,
title = {Dual-target CD19/BCMA CAR-T cell therapy in systemic lupus erythematosus and myasthenia gravis: current evidence and future directions},
author = {Alsenawi, Khaled W.D. and Alasbahi, Massa Salahi and Erdağ, Berrin},
journal = {Clinical Immunology Communications},
doi = {10.1016/j.clicom.2026.100145},
url = {https://www.sciencedirect.com/science/article/pii/S2772613426000326?dgcid=rss_sd_all}
}